Among TAVI patients who have an indication for anticoagulation, direct oral anticoagulants (DOACs) appear to provide better outcomes than do vitamin K antagonists (VKAs), according to a French ...

Doctor giving emotional support to a senior patient using face mask In a landmark trial presented at AHA 2021, researchers aimed to understand the safety and efficacy of direct oral anticoagulants vs ...

NEW YORK, NY—Patients undergoing TAVI who have an indication for oral anticoagulation are less likely to die over 5 years of follow-up if they’re discharged on a direct oral anticoagulant (DOAC) ...

Results from the FRAIL-AF study, being presented at the European Society of Cardiology 2023 Congress, surprised the investigators. In a study that will likely turn heads among cardiologists, findings ...

Contrary to expectations, vitamin K antagonists (VKAs) reduced the risk for ischemic stroke and death compared with the factor Xa inhibitor rivaroxaban (Xarelto, Janssen) in patients with rheumatic ...

Janssen has announced results from its Phase 3b exploratory trial evaluating the efficacy of Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKAs) for treating and reducing the risk ...

A recent study published in JAMA found an association between treatment with dicloxacillin and a decrease in international normalized ratio (INR) levels among patients taking vitamin K antagonists ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Vitamin K antagonists have been extensively used as the ...

Prognostic factors of survival after radiotherapy for metastases to the spinal column and a scoring system of survival: Review of 530 patients in Shizuoka Cancer Center Hospital CLOT N=676 Dalteparin ...

Close-up of home caregiver and senior woman holding hands The authors observed that AF patients taking DOACs are less likely to experience dementia or cognitive decline than those prescribed vitamin K ...